title: Genotype- and phenotype-directed antiplatelet therapy selection in patients with acute coronary syndromes.
abstract: Although dual antiplatelet therapy (DAPT) has been a standard treatment in patients with acute coronary syndrome (ACS) for over a decade, only recently have therapeutic options beyond aspirin and clopidogrel become available. Additional treatment options are particularly useful because of the documented history of variability in antiplatelet response. This article reviews the current treatment options for DAPT in ACS, and reviews both genotype- and phenotype-guided methods for determining optimal antiplatelet therapy for patients with ACS. Additionally, recommendations from current guidelines as well as expert commentary are provided for the use of available testing methods to determine optimal DAPT for ACS patients.
authors.affiliation: Department of Medicine, University of Illinois, Chicago, IL, USA.
authors.forename: Sahar
authors.initials: S
authors.lastname: Ismail
authors.forename: Yee Ming
authors.initials: YM
authors.lastname: Lee
authors.forename: Meet
authors.initials: M
authors.lastname: Patel
authors.forename: Julio D
authors.initials: JD
authors.lastname: Duarte
authors.forename: Amer K
authors.initials: AK
authors.lastname: Ardati
mesh_terms: D054058:Acute Coronary Syndrome / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use*; D005838:Genotype; D006801:Humans; D018579:Patient Selection; D010641:Phenotype; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D001241:Aspirin
keywords: P2Y12 Inhibitors; acute coronary syndrome; antiplatelet; aspirin; clopidogrel; personalized medicine; pharmacogenetic; prasugrel; precision medicine; ticagrelor